FCX vs IRD · P/E 38, rev $25.45B vs rev $11.0M
Freeport-McMoran Copper & Gold Inc (FCX) versus Opus Genetics, Inc. (IRD) — a side-by-side from cached financials, not a winner call.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Opus Genetics, Inc. (IRD) is a biotechnology company listed on US.
Latest reported FCX revenue for 2024-12-31 was $25.45B. Net income was $4.40B. Revenue was up 11.4% from 2023-12-31 to 2024-12-31. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Latest reported IRD revenue for 2024-12-31 was $11.0M. Net income was -$57.5M. Revenue was down 42.3% from 2023-12-31 to 2024-12-31. IRD currently screens at market cap $35.7M.
FCX currently screens at market cap $67.80B and trailing P/E 38.0. IRD currently screens at market cap $35.7M.
Not investment advice. Open the FCX and IRD stock pages for the full models.
Not investment advice.